Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, ...

CD58 status was evaluated in patients with r/r B-ALL before CAR-T therapy, and the patients who failed or relapsed after CAR-T. Among 274 pediatric and adult patients prior to exposure to CAR-T cells ...

Carfilzomib is under development for the treatment of newly diagnosed primary plasma cell leukemia, kidney, amyloidosis, hematological malignancies including lymphoma, T-Cell lymphomas, relapsed or ...

Induction treatment for childhood acute lymphoblastic leukaemia (ALL) The aim of induction is to get rid of as many leukaemia cells as possible. It's also called remission induction. In remission ...

ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell ...

The FDA has approved Autolus Therapeutics’ Aucatzyl (obecabtagene autoleucel or obe-cel), a chimeric antigen receptor T-cell therapy for adult patients with relapsed/refractory B-cell acute ...

STEVE GSCHMEISSNER / SCIENCE PHOTO LIBRARY / Getty Images Overview A blast cell is an immature cell in the bone marrow that gives rise to mature lines of blood cells, In the case of lymphoblastic ...

A myeloid stem cell can then develop into several other types of cells, including myeloblasts, while a lymphoid stem cell matures into a lymphoblast. Myeloblasts then mature into white blood cells ...

Her initial CBC revealed a white cell count of 890,000 x 10 3 /μl, with 92% abnormal white blood cells.

The biologics license application (BLA) for obecabtagene autoleucel (obe-cel; AUTO1) for the treatment of adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) has ...